webinar register page

Webinar banner
Accelerate your Translational Research with TIA


Sep 14, 2021 11:34 AM

Webinar logo
* Required information


Dr Stuart Newman
CEO @Therapeutic Innovation Australia
Since completing a PhD in Antarctic Biology from the University of Tasmania, Stuart has built up considerable experience of science policy, pharmaceutical R&D, grant funding, IP management, business development and commercialisation in the university and not-for-profit sectors. Since 2017 he has been the CEO of Therapeutic Innovation Australia Ltd, which manages research infrastructure funding from the Department of Education's NCRIS scheme. Under his leadership, TIA has focussed investment on the gap between research and development of high-value therapeutics, including pharmaceuticals, biologics, vaccines and cell & gene therapies. He also devised an innovative infrastructure access voucher scheme to enables early-stage projects to access the right expertise at the right time. He is based at the Translational Research Institute in Brisbane and is a graduate of the Australian Institute of Company Directors.
Dr Heather Donaghy
Scientific Engagement Manager, Cell & Gene Therapies @Therapeutic Innovation Australia
Heather completed her PhD in viral immunology at Imperial College before moving to Sydney for a post-doc at Westmead. Since then she has had a career spanning basic science, preclinical and clinical research in immunology and oncology. ​ Heather has a track record of enabling and developing research programs including proof of concept studies and commercially successful projects. Heather works with researchers to understand their unique circumstances. She has diverse project management expertise, from planning and executing preclinical studies to database migration. ​ Heather brings her diverse experience to TIA to enable researchers within the cell and gene space to access manufacturing facilities and enhance translation of novel therapies to the clinic.
Dr John Parisot
Business Development Manager, Small Molecules @Therapeutic Innovation Australia
John has over 20 years’ experience in human based healthcare R&D for pharmaceutical companies, biotech’s and world leading academic institutes. He is an experienced stakeholder manager and collaborator who has succeeded in early stage drug development and clinical trials management gaining a comprehensive understanding of the path to market for new drug entities. Project management from high throughput drug discovery for multiple diseases encompassing cancer, tropical diseases and immunotherapeutic targets, through to clinical trials with a deep understanding of the pre-clinical to regulatory pathways to develop new therapies for approval by the TGA & FDA.
Mr Ben Hughes
Director of Strategic Development, National Biologics Facility @Therapeutic Innovation Australia
Ben brings over 20 years of experience in commercializing biologics with a proven track record of developing successful teams and implementing compliant systems for cGMP manufacturing in both Australia and the US. Ben has extensive experience in facility design and start-up, and delivering for his customers in bringing a broad range of vaccines and biologics products through tech transfer from process development through to GMP manufacture and commercialization. Ben previously worked at Patheon by Thermo Fisher, The University of Queensland, Merck and Co, Inc., and CSL, and is a graduate of the University of New South Wales Bioprocess (Chemical) Engineering.
Professor Alex Loukas
NHMRC Senior Principal Research Fellow and Distinguished Professor @James Cook University
Alex Loukas is a NHMRC Senior Principal Research Fellow and Distinguished Professor at James Cook University. He obtained his BSc and PhD from University of Queensland, conducted postdoctoral work at the University of Edinburgh, and has held faculty positions at George Washington University, Queensland Institute of Medical Research and James Cook University. His research focusses on host-parasite interactions, and exploiting this to develop anti-helminth subunit vaccines and diagnostics, as well as biologics for treating inflammatory and metabolic diseases. His work is currently funded by the Australian and US governments and philanthropic and venture capital groups. He is founder of Macrobiome Therapeutics, a start-up biotech company that is developing biologics for inflammatory diseases. He has received numerous awards for his research, including a Fulbright Senior Scholarship to work at University of California, and he is a fellow of the Australian Society for Parasitology.
Mr Greg Santamaria
CEO @Cyclotek Pty Ltd
Greg Santamaria is a part owner, Director and CEO of Cyclotek Pty Ltd and its subsidiaries, manufacturing diagnostic radiopharmaceuticals for cancer and neurological diseases. The Cyclotek group has expanded in the last ten years from one facility to six facilities within Australia and New Zealand with eighty staff. Cyclotek is now expanding into manufacturing therapeutic radiopharmaceuticals for Australia, New Zealand and South East Asia. Greg hold an independent directorship on the board of ANSTO Nuclear Medicine Pty Ltd and chair it’s Risk and Audit Committee. He is also an independent director of Freo2 Australia Foundation Ltd where the focus is on supply of “fit-for-country” oxygen system into sub-Africa and low economic regions. In addition, he also owns Gateway Productions where they develop musical productions focused towards family entertainment.